ArticleViruses2026
Differentiated Contact Tracing for Emerging Zoonotic Hantavirus and Ebolavirus Infections: Lessons from the 2026 Andes Virus (MV Hondius) and Bundibugyo Virus Outbreaks.
Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating mathematical modelling and artificial intelligence to combat emerging viral syndemics: A systematic review.New microbes and new infections · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In May 2026, two outbreaks occurred at once: an Andes virus outbreak aboard the MV Hondius expedition cruise ship (13 cases (12 laboratory-confirmed and 1 probable), 3 deaths, and more than 600 contacts traced across 32 countries and territories; passengers and crew from 23 countries; data as of 22 June 2026) and a Bundibugyo virus disease (BDBV) outbreak in Central Africa (more than 1000 laboratory-confirmed cases and more than 250 confirmed deaths in the Democratic Republic of the Congo and Uganda; data as of 22 June 2026). The two pathogens diverge sharply in their transmission epidemiology. Aboard the MV Hondius, person-to-person transmission was sustained across three generations from a single index case, and one asymptomatic, PCR-positive contact later developed symptoms, indicating pre-symptomatic ANDV RNA detection, although the extent to which this corresponds to infectiousness and onward transmission remains uncertain. BDBV, on current evidence, has not been documented to sustain pre-symptomatic transmission as a major driver of its outbreaks, which allows for contact tracing of different timing and intensity. This Perspective draws together the epidemiological data from the MV Hondius outbreak, the endemic-region experience (Chile's 2021-2025 secondary attack rate of 5.7%; Argentina's 1996 El Bolsón and 2018 Epuyén outbreaks), the molecular pathogenesis, the diagnostic platforms, the therapeutic pipeline (favipiravir, tocilizumab, Icatibant) and the vaccine strategies (USAMRIID DNA vaccine, phase 1 completed). We set the contact-tracing and active-surveillance protocols applied to ANDV against the less stringent protocols that may suffice for BDBV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.